Kaplan–Meier statistical analysis of 100 patients with a follow-up >12 months predicting remission
| Factor . | Three-year CSR rate (%) . | P-valuea . | Three-year remission rate (%) . | P-valuea . |
|---|---|---|---|---|
| Age (12–82 years) | ||||
| <33 (n = 50) | 20.9 | 0.06b | 28.0 | 0.99 |
| >33 (n = 50) | 7.7 | 28.6 | ||
| Gender | 0.32 | 0.57 | ||
| Female (n = 73) | 18.2 | 26.3 | ||
| Male (n = 27) | 4.5 | 34.9 | ||
| AChR antibodies | 0.86 | 0.88 | ||
| Positive (n = 91) | 14.5 | 28.1 | ||
| Seronegative (n = 9) | 11.1 | 22.2 | ||
| Preoperative MGFA | 0.10b | 0.28 | ||
| Class I–II (n = 37) | 20.2 | 33.5 | ||
| Class III–IV (n = 63) | 11.2 | 24.2 | ||
| Histology | 0.13b | 0.46 | ||
| Benign thymic tissue (n = 73) | 17.7 | 26.5 | ||
| Thymoma (n = 27) | 5.6 | 34.1 | ||
| Preoperative duration symptoms | 0.37 | 0.98 | ||
| <12 months (n = 43), range (0–12 months) | 12.2 | 30.8 | ||
| >12 months (n = 57), range (12–144 months) | 16.0 | 26.8 | ||
| Type of MG | ||||
| Early onset (n = 81) | 20.4 | 0.08b | 28.7 | 0.71 |
| Late onset (n = 19) | 0.0 | 25.8 | ||
| Preoperative prednisolone | ||||
| No (n = 50) | 25.9 | 0.014b | 36.1 | 0.20 |
| Yes (n = 50) | 6.2 | 19.0 | ||
| Factor . | Three-year CSR rate (%) . | P-valuea . | Three-year remission rate (%) . | P-valuea . |
|---|---|---|---|---|
| Age (12–82 years) | ||||
| <33 (n = 50) | 20.9 | 0.06b | 28.0 | 0.99 |
| >33 (n = 50) | 7.7 | 28.6 | ||
| Gender | 0.32 | 0.57 | ||
| Female (n = 73) | 18.2 | 26.3 | ||
| Male (n = 27) | 4.5 | 34.9 | ||
| AChR antibodies | 0.86 | 0.88 | ||
| Positive (n = 91) | 14.5 | 28.1 | ||
| Seronegative (n = 9) | 11.1 | 22.2 | ||
| Preoperative MGFA | 0.10b | 0.28 | ||
| Class I–II (n = 37) | 20.2 | 33.5 | ||
| Class III–IV (n = 63) | 11.2 | 24.2 | ||
| Histology | 0.13b | 0.46 | ||
| Benign thymic tissue (n = 73) | 17.7 | 26.5 | ||
| Thymoma (n = 27) | 5.6 | 34.1 | ||
| Preoperative duration symptoms | 0.37 | 0.98 | ||
| <12 months (n = 43), range (0–12 months) | 12.2 | 30.8 | ||
| >12 months (n = 57), range (12–144 months) | 16.0 | 26.8 | ||
| Type of MG | ||||
| Early onset (n = 81) | 20.4 | 0.08b | 28.7 | 0.71 |
| Late onset (n = 19) | 0.0 | 25.8 | ||
| Preoperative prednisolone | ||||
| No (n = 50) | 25.9 | 0.014b | 36.1 | 0.20 |
| Yes (n = 50) | 6.2 | 19.0 | ||
Remission rate: CSR + PR; AChR: acetylcholine receptor; MGFA: Myasthenia Gravis Foundation of America; MG: myasthenia gravis.
aUnadjusted P-value performed by log rank.
bCox proportional hazard regression analysis showed no significant hazard ratio.
Kaplan–Meier statistical analysis of 100 patients with a follow-up >12 months predicting remission
| Factor . | Three-year CSR rate (%) . | P-valuea . | Three-year remission rate (%) . | P-valuea . |
|---|---|---|---|---|
| Age (12–82 years) | ||||
| <33 (n = 50) | 20.9 | 0.06b | 28.0 | 0.99 |
| >33 (n = 50) | 7.7 | 28.6 | ||
| Gender | 0.32 | 0.57 | ||
| Female (n = 73) | 18.2 | 26.3 | ||
| Male (n = 27) | 4.5 | 34.9 | ||
| AChR antibodies | 0.86 | 0.88 | ||
| Positive (n = 91) | 14.5 | 28.1 | ||
| Seronegative (n = 9) | 11.1 | 22.2 | ||
| Preoperative MGFA | 0.10b | 0.28 | ||
| Class I–II (n = 37) | 20.2 | 33.5 | ||
| Class III–IV (n = 63) | 11.2 | 24.2 | ||
| Histology | 0.13b | 0.46 | ||
| Benign thymic tissue (n = 73) | 17.7 | 26.5 | ||
| Thymoma (n = 27) | 5.6 | 34.1 | ||
| Preoperative duration symptoms | 0.37 | 0.98 | ||
| <12 months (n = 43), range (0–12 months) | 12.2 | 30.8 | ||
| >12 months (n = 57), range (12–144 months) | 16.0 | 26.8 | ||
| Type of MG | ||||
| Early onset (n = 81) | 20.4 | 0.08b | 28.7 | 0.71 |
| Late onset (n = 19) | 0.0 | 25.8 | ||
| Preoperative prednisolone | ||||
| No (n = 50) | 25.9 | 0.014b | 36.1 | 0.20 |
| Yes (n = 50) | 6.2 | 19.0 | ||
| Factor . | Three-year CSR rate (%) . | P-valuea . | Three-year remission rate (%) . | P-valuea . |
|---|---|---|---|---|
| Age (12–82 years) | ||||
| <33 (n = 50) | 20.9 | 0.06b | 28.0 | 0.99 |
| >33 (n = 50) | 7.7 | 28.6 | ||
| Gender | 0.32 | 0.57 | ||
| Female (n = 73) | 18.2 | 26.3 | ||
| Male (n = 27) | 4.5 | 34.9 | ||
| AChR antibodies | 0.86 | 0.88 | ||
| Positive (n = 91) | 14.5 | 28.1 | ||
| Seronegative (n = 9) | 11.1 | 22.2 | ||
| Preoperative MGFA | 0.10b | 0.28 | ||
| Class I–II (n = 37) | 20.2 | 33.5 | ||
| Class III–IV (n = 63) | 11.2 | 24.2 | ||
| Histology | 0.13b | 0.46 | ||
| Benign thymic tissue (n = 73) | 17.7 | 26.5 | ||
| Thymoma (n = 27) | 5.6 | 34.1 | ||
| Preoperative duration symptoms | 0.37 | 0.98 | ||
| <12 months (n = 43), range (0–12 months) | 12.2 | 30.8 | ||
| >12 months (n = 57), range (12–144 months) | 16.0 | 26.8 | ||
| Type of MG | ||||
| Early onset (n = 81) | 20.4 | 0.08b | 28.7 | 0.71 |
| Late onset (n = 19) | 0.0 | 25.8 | ||
| Preoperative prednisolone | ||||
| No (n = 50) | 25.9 | 0.014b | 36.1 | 0.20 |
| Yes (n = 50) | 6.2 | 19.0 | ||
Remission rate: CSR + PR; AChR: acetylcholine receptor; MGFA: Myasthenia Gravis Foundation of America; MG: myasthenia gravis.
aUnadjusted P-value performed by log rank.
bCox proportional hazard regression analysis showed no significant hazard ratio.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
